Eisai, Biogen Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit
Eisai (4523.T) and Biogen (BIIB) reported five-year data from the Clarity AD trial, showing sustained benefits from continuous Leqembi treatment in early Alzheimer's patients. The study found a 36% reduction in disease progression risk and 49% reduction in progression to moderate or severe Alzheimer's. No new safety concerns were identified. 4523.T and BIIB have traded between 3,660.00-5,323.00 JPY and $160.36-$261.00 USD, respectively, over the past 52 weeks.
How this was made
The 30-second read
Why it matters
The data show sustained cognitive benefit and no new safety signals, which could improve revenue expectations for both companies.
Market read
First‑time disclosure of long‑term efficacy data is material for investors in both firms and the broader neuro‑degeneration space.
What to watch
Potential reimbursement challenges and competition from other anti‑amyloid drugs.
Background
The article reports the first public release of five‑year extension data from the Phase 3 Clarity AD trial for lecanemab.
Ticker impact
Biogen co‑presented the same five‑year lecanemab results, a primary disclosure for the company.
upward pressure as market absorbs favorable efficacy results
First report of extended efficacy reduces uncertainty and could improve revenue forecasts.
Market effects
Strengthens the Alzheimer’s‑treatment biotech sector and may lift peer valuations.
Positive for Japanese pharma (Eisai) and US biotech (Biogen) markets.
Adds confidence to amyloid‑targeting therapies worldwide.
Counterpoint
Long‑term safety still unknown; market may have priced in optimism already.
Key entities
- companyEisai Co., Ltd.
Japanese pharmaceutical firm developing lecanemab.
- companyBiogen Inc.
US biotech partner co‑developing lecanemab.



